Zymeworks Inc. (ZYME)

Market Cap	1.00B
Revenue (ttm)	62.20M
Net Income (ttm)	-113.67M
Shares Out	68.88M
EPS (ttm)	-1.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	374,217
Open	14.67
Previous Close	14.77
Day's Range	14.43 - 14.76
52-Week Range	7.97 - 17.70
Beta	1.16
Analysts	Buy
Price Target	19.00 (+30.58%)
Earnings Date	Oct 31, 2024

About ZYME

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 28, 2017
• Employees: 278
• Stock Exchange: NASDAQ
• Ticker Symbol: ZYME
• Website: https://www.zymeworks.com

Analyst Forecast

According to 5 analysts, the average rating for ZYME stock is "Buy." The 12-month stock price forecast is $19.0, which is an increase of 30.58% from the latest price.

Price Target

$19.0

(30.58% upside)

Analyst Consensus: Buy